BioXcel Therapeutics - Chapter 11 DIP Terms

BioXcel Therapeutics obtained interim approval for a $77.25 million senior secured superpriority priming DIP facility agented by Oaktree Fund Administration and funded by Oaktree Capital Management-managed funds and affiliates of the Qatar Investment Authority. The facility pairs $19 million of new money, advanced in a $9.5 million draw upon entry of the interim order and up to $9.5 million more upon entry of the final order, with a cashless, dollar-for-dollar roll-up of up to $58.25 million of prepetition secured obligations. It bears 13% interest payable in cash on the new money loans and in kind on the roll-up loans, a 4% exit fee and a Jan. 27, 2027 maturity, and requires entry of a sale order within 60 days and a plan effective date within 115 days of the Aug. 27, 2026 petition date.

DIP Terms

Borrower(s) / Guarantor(s)

Agent / Lender(s)

DIP Commitments

Cash Collateral

Interest Rate

Fees

Maturity

Case Milestones

Events of Default and Remedies

Carve Out

Use of Proceeds

Credit Bid

Avoidance Actions

Challenge Period and Budget

Permitted Variance

Financial Covenant

Liens and Priorities

Adequate Protection

Prepetition Secured Parties

Releases

Waivers

Governance Conditions